FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER'S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alzheimer's-AAIC2025

More Like This

PR Newswire associated0

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED RECRUITING FOR RESEARCH & REDUCE WAIT TIMES

PR Newswire associated0

RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom